Evaluation of the Safety and Efficacy of the ReLARC Inserter During the Insertion Procedure of GYNEFIX Intrauterine Copper Bearing Contraceptive Device With a Follow-up of 3 Years.

ConditionContraception
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-48
SponsorUniversity Hospital, Ghent

About this trial

Insertion under vision such as hysteroscopy allows the ability to visualize the uterus prior to insertion, to assess uterine compatibility and the assurance of proper device placement. ReLARC® is a GyneFix® device intended to be inserted via hysteroscopy. Hysteroscopic insertion of the device allows direct visualization of the procedure, which makes it extremely safe.

This multicentre, open-label study will take place at the Women's Clinic of Ghent University Hospital in Belgium (International Coordinating Centre) and at the University Hospital AOU Federico II of Naples in Italy.

Primary aim:

To evaluate the safety of the ReLARC® inserter during the insertion procedure of GyneFix® intrauterine copper bearing contraceptive devices by means of successful placement with adequate position during follow-up evaluations.

Providing no complications develop, participants will remain in the study for 3 years. 120 women will be enrolled.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Generally healthy women, 18 - 48 years of age and not having a contraindication for hysteroscopy

Be willing to come back for the follow-ups

Be willing to refrain from having intercourse the first two weeks and using tampons and menstrual cups in the first 2 months, following insertion

Sign a written informed consent

Disqualifiers

T and Y shaped uterus

U1, dysmorphic uterus (abnormal myometrium may result in bad device fixation)

Complete septate U2b uterus

Bicorporal U3-U6 uterus

Trial design

Design model

Single group

Treatments tested in this trial

  • ReLARC

    Device

    ReLARC® is a GyneFix® device intended to be inserted via hysteroscopy. Hysteroscopic insertion of the device allows direct visualization of the procedure, which makes it extremely safe.

Treatment groups

120 Participants
are divided into 2 treatment groups
Group A: ReLARC 3Other 1 intervention
Group B: ReLARC 10Other 1 intervention

Trial outcomes

Primary outcomes

1

Positioning of the ReLARC IUD

To evaluate the position of the ReLARC® IUD to confirm the succesful placement of the IUD with the ReLARC inserter during every follow-up visit.

Time frame
3 years

Secondary outcomes

1

Ease of insertion

1\. The ease of the insertion (hysteroscope and ReLARC® device) by the following scale: 1. Insertion went smoothly. 2. I had little trouble while inserting the device but experienced this as a not important delay in my surgical act. 3. Insertion was rather difficult. 4. Insertion was time consuming, difficult, and dangerous. 5. Insertion was not possible due to technical issues or medical reasons.

Time frame
During Insertion visit
2

Learning curve of ReLARC insertion

2\. The learning curve of ReLARC® insertion, that starts after introducing the scope in the cervix and ends when the thread is cut and looped. This will be reported in minutes.

Time frame
During Insertion visit
3

Pain score

the participant's pain by a Visual Analogue Scale-VAS (1. no pain, 2. mild pain, 3. nasty pain, 4. severe pain, 5. unbearable pain) will be described.

Time frame
During Insertion visit
4

patient satisfactory

The patient satisfactory score will be determined at every follow-up visit (4-8 weeks after insertion; 1 year after insertion, 2 years after insertion and 3 years after insertion)

Time frame
3 years after insertion

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University Hospital, Ghent

Lead sponsor

Federico II University

Collaborator